Ipca Laboratories Ltd has informed BSE that The Global Fund, Geneva, Switzerland vide their letter dated April 04, 2016 (which was transmitted to the Company vide their e-mail dated April 06, 2016), have informed the Company that in the light of the warning letter issued to the Company by the United States Federal Drug Regulatory Authority (US FDA) on January 29, 2016, they have re-assessed the situation and following a risk consideration exercise, will not allocate any volume of Artemisinin based Combination Therapy (ACTs) to the Company and that they will only source ACTs from other pre-qualified suppliers that have no outstanding issues with the regulators.
Ask Value Research 
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.
